Discover how Wegovy for women delivers substantial weight loss and reduces the risk of migraines and depression across all menopausal stages, according to new Novo Nordisk data.
The recent Hympavzi European Commission Approval marks a milestone for the hemophilia community, introducing the first once-weekly anti-TFPI therapy for patients with inhibitors in the EU.
Merck delivers a robust Q1 2026 performance with €5.1 billion in sales. Driven by its Life Science and Electronics sectors, the company has officially upgraded its full-year outlook.
GenScript has launched the TurboCHOâ„¢ Protein Expression Kit in Boston, offering researchers the fastest path to high-titer antibodies with a proprietary transfection system and high-performing CHO cell line.
Novo Nordisk has unveiled groundbreaking clinical sub-analyses at the European Congress on Obesity (ECO) 2026, revealing that high-dose semaglutide (7.2 mg) can lead to nearly 28% weight loss in specific patient groups while preserving vital muscle health.
Johnson & Johnson reinforces its leadership in neuropsychiatry, presenting pivotal data for seltorexant and aticaprant at the 2024 APA and ASCP meetings.
Charles River Laboratories First Quarter 2026 Results were officially released, showcasing a company in the midst of a significant strategic transformation. The Wilmington-based contract research [Read More…]
Understanding how hantavirus spreads is the first critical step in protecting yourself and your family from a rare but highly dangerous respiratory disease. Whether you are cleaning out an old barn, sweeping a dusty attic, or opening up a long-closed summer cabin, knowing the risks associated with rodent-borne pathogens can quite literally save your life. Hantaviruses are primarily excreted in the urine, droppings, and saliva of infected wild rodents, and most human infections occur when these substances are disturbed and become airborne, allowing microscopic viral particles to be easily inhaled.
Gilead Sciences reports a strong Q1 2026 with $6.96 billion in revenue, driven by its industry-leading HIV portfolio and the rapid uptake of Yeztugo, despite acquisition-related guidance adjustments.
Released in May 2026, the Novo Nordisk Q1 2026 report showcases a complex but optimistic financial picture, highlighting a massive revenue beat fueled by the record-breaking U.S. launch of the Wegovy pill, prompting the pharmaceutical giant to raise its full-year guidance.
